Apitegromab Safely Counters Muscle Growth Suppressor, Phase 1 Trial Finds

Apitegromab Safely Counters Muscle Growth Suppressor, Phase 1 Trial Finds

294572

Apitegromab Safely Counters Muscle Growth Suppressor, Phase 1 Trial Finds

Apitegromab, Scholar Rock’s muscle-directed therapy for spinal muscular atrophy (SMA), was generally safe and showed dose-dependent accumulation and clearance of the inactive form of myostatin, a muscle growth suppressor, in healthy volunteers, according to data from a Phase 1 clinical trial. These findings, published in the journal Advanced in Therapy, “provided an important foundation to support advancing the development of apitegromab,” Yung Chyung, MD, Scholar Rock’s chief medical officer, said in a press release. The therapy is…

You must be logged in to read/download the full post.